- Protein Name
- Calcium/calmodulin-dependent protein kinase type II subunit delta
- Gene Name
- CAMK2D
- Organism
-
Homo sapiens
- Function
- Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules to regulate heart function. In its activated form, is involved in the pathogenesis of dilated cardiomyopathy and heart failure. Contributes to cardiac decompensation and heart failure by regulating SR Ca(2+) release via direct phosphorylation of RYR2 Ca(2+) channel on 'Ser-2808'. In the nucleus, phosphorylates the MEF2 repressor HDAC4, promoting its nuclear export and binding to 14-3-3 protein, and expression of MEF2 and genes involved in the hypertrophic program. Is essential for left ventricular remodeling responses to myocardial infarction. In pathological myocardial remodeling acts downstream of the beta adrenergic receptor signaling cascade to regulate key proteins involved in ECC. Regulates Ca(2+) influx to myocytes by binding and phosphorylating the L-type Ca(2+) channel subunit beta-2 CACNB2. In addition to Ca(2+) channels, can target and regulate the cardiac sarcolemmal Na(+) channel Nav1.5/SCN5A and the K+ channel Kv4.3/KCND3, which contribute to arrhythmogenesis in heart failure. Phosphorylates phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2, contributing to the enhancement of SR Ca(2+) uptake that may be important in frequency-dependent acceleration of relaxation (FDAR) and maintenance of contractile function during acidosis. May participate in the modulation of skeletal muscle function in response to exercise, by regulating SR Ca(2+) transport through phosphorylation of PLN/PLB and triadin, a ryanodine receptor-coupling factor.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| AAS |
19 |
19 |
19.0 |
| MT3 |
3 |
3 |
3.0 |
| ATP |
30 |
1 |
9.0 |
| DFG |
15 |
15 |
15.0 |
| CMP |
12 |
12 |
12.0 |
| EDI |
13 |
10 |
13.0 |
| DRS |
14 |
5 |
5.0 |
| PDIG |
15 |
15 |
15.0 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
AAS site |
MT3 site |
LBP site |
ATP site |
DEF site |
DFG site |
CMP site |
PMP site |
EDI site |
DRS site |
PDIG site |
PIF site |
| Total Druggable Structures per Site |
0 |
1 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2VN9
|
0 |
0 |
0 |
0 |
19 |
0 |
15 |
0 |
0 |
13 |
5 |
0 |
0 |
|
2WEL
|
0 |
19 |
3 |
0 |
30 |
0 |
0 |
12 |
0 |
10 |
14 |
15 |
0 |